CAPE TOWN, South Africa and TUSTIN, Calif., Oct. 13 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. a clinical stage biopharmaceutical company developing monoclonal antibodies for cancer and serious viral infections, today reported the company's anti-phosphatidylserine (anti-PS) technology platform will be discussed in scientific sessions at the AIDS Vaccine 2008 conference in Cape Town, South Africa. Peregrine is developing a new class of anti-PS monoclonal antibody immunotherapeutics that stimulate the body's immune system to respond to a viral attack by targeting and binding to cellular components that become exposed on the surface of enveloped viruses and on virally infected cells, but not on healthy cells. "Following on the heels of our recently awarded U.S. government contract to assess our anti-PS antibodies...
[read full story]
Your Web Site
